Clinical Trials

Find trials by condition, location & phase

Drug Monographs

Browse drug monographs and information

Explore organizations and their profiles

Latest updates on trials and healthcare

Approved products by global authorities

AI-Powered Research

Discover powerful insights with advanced AI analysis tools for clinical trials.

Premium Access

Get unlimited access to our comprehensive pharmaceutical database and analytics.

GREEN CROSS CORPORATION

🇮🇳India

Country: 🇮🇳India

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Safety, Efficacy and Pharmacokinetics of GreenGene™ F to Previously Treated Patients With Severe Hemophilia A

Phase 3

Conditions: Hemophilia A

Interventions: Biological: GreenGene™ F and an approved recombinant Factor VIII product
Biological: GreenGene™ F

First Posted Date: 2012-06-14

Last Posted Date: 2014-07-03

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 124

Registration Number: NCT01619046

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Los Angeles Orthopaedic Hospital - Hemophilia Treatment Center, Los Angeles, California, United States
🇺🇸
Harbor - UCLA Pediatrics, Torrance, California, United States

and more 31 locations

Safety and Pharmacokinetics Study of Healthy Male Adults When Repeatedly Administered Through Intravenous Injection

Phase 1

Completed

Conditions: Hepatitis B

Interventions: Biological: GC1102
Other: JW normal saline

First Posted Date: 2012-05-25

Last Posted Date: 2014-01-03

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 36

Registration Number: NCT01606163

Locations: 🇰🇷
Department of clinical pharmacology and therapeutics, Seoul, Korea, Republic of

To Evaluate the Safety of 'Shinbaro Capsule'in Patients With Osteoarthritis

Phase 4

Completed

Conditions: Osteoarthritis

Interventions: Drug: Shinbaro Capsule

First Posted Date: 2012-05-23

Last Posted Date: 2013-11-13

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 761

Registration Number: NCT01604239

Locations: 🇰🇷
Kyungpook national university hospital, Daegu, Kyungpook, Korea, Republic of
🇰🇷
BundangCha Hospital, Bundang, Korea, Republic of
🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of

and more 15 locations

Efficacy and Safety of Recombinant Factor VIII (GreenGene) in Patients With Hemophilia A

Phase 3

Completed

Conditions: Hemophilia A

Interventions: Drug: GreenGene

First Posted Date: 2012-04-02

Last Posted Date: 2012-04-02

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 71

Registration Number: NCT01568580

Efficacy and Safety of Shinbaro Capsule

Phase 3

Completed

Conditions: Osteoarthritis

Interventions: Drug: Shinbaro Capsule
Drug: Celebrex

First Posted Date: 2012-02-17

Last Posted Date: 2012-02-17

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 198

Registration Number: NCT01535417

Study of Combined Therapy of Aspirin and "IVIG-SN" in Kawasaki Disease

Phase 4

Completed

Conditions: Kawasaki Disease

Interventions: Drug: immunoglobulin G

First Posted Date: 2012-02-02

Last Posted Date: 2012-09-20

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 45

Registration Number: NCT01524939

Locations: 🇰🇷
Wonju christian Hospital, Wonju, Kang-won, Korea, Republic of
🇰🇷
Gachon University Gil Hospital, Incheon, Korea, Republic of
🇰🇷
Asan Medical center, Seoul, Korea, Republic of

and more 4 locations

Phase 3 Study of Immune Globulin Intravenous (Human)IVIG-SN™ in Subjects With Primary Immunodeficiency

Phase 3

Completed

Conditions: Immunologic Deficiency Syndrome

Interventions: Drug: Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™

First Posted Date: 2011-08-01

Last Posted Date: 2014-01-10

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 45

Registration Number: NCT01406470

Locations: 🇺🇸
University of Alabama Hospital, Birmingham, Alabama, United States
🇺🇸
Allergy Associates of the Palm Beaches, North Palm Beach, Florida, United States
🇺🇸
Rush University Medical Center, Chicago, Illinois, United States

and more 8 locations

To Evaluate the Effectiveness(Immunogenicity) and Safety of 'GC1107' Administered Intramuscularly in Healthy Children

Phase 2

Completed

Conditions: Bacterial Infections

Interventions: Biological: GC1107
Biological: TD_PUR INJ / SK Td vaccine

First Posted Date: 2011-07-26

Last Posted Date: 2015-01-26

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 311

Registration Number: NCT01402713

Locations: 🇰🇷
The catholic university of Korea, Seoul st. mary's hospital, Banpo-dong, Seoul, Korea, Republic of

Study to Evaluate the Safety and Immunogenicity of MG1109 in Healthy Adult Volunteers

Phase 1

Completed

Conditions: Influenza

Interventions: Biological: Step 2
Biological: Step 1

First Posted Date: 2011-07-08

Last Posted Date: 2014-11-21

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 346

Registration Number: NCT01389466

Locations: 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷
Inha University Hospital, Inchon, Korea, Republic of
🇰🇷
Korea University Guro Hospital, Seoul, Korea, Republic of

and more 1 locations

To Evaluate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Erythropoietin

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: GC1113
Drug: Darbepoetin alfa

First Posted Date: 2011-06-02

Last Posted Date: 2012-07-19

Lead Sponsor: Green Cross Corporation

Target Recruit Count: 100

Registration Number: NCT01363934

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy